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Abstract
Objectives To determine the presence and morphology of
subsolid pulmonary nodules (SSNs) in a non-screening setting
and relate them to clinical and patient characteristics.
Methods A total of 16,890 reports of clinically obtained chest
CT (06/2011 to 11/2014, single-centre) were searched describ-
ing an SSN. Subjects with a visually confirmed SSN and at
least two thin-slice CTs were included. Nodule volumes were
measured. Progression was defined as volume increase ex-
ceeding the software interscan variation. Nodule morphology,
location, and patient characteristics were evaluated.
Results Fifteen transient and 74 persistent SSNs were includ-
ed (median follow-up 19.6 [8.3–36.8] months). Subjects with
an SSNwere slightly older than thosewithout (62 vs. 58 years;
p=0.01), but no gender predilection was found. SSNs were
mostly located in the upper lobes.Women showed significant-
ly more often persistent lesions than men (94 % vs. 69 %;
p=0.002). Part-solid lesions were larger (1638 vs. 383 mm3;
p < 0.001) and more often progressive (68 % vs. 38 %;
p = 0.02), compared to pure ground-glass nodules.
Progressive SSNs were rare under the age of 50 years.
Logistic regression analysis did not identify additional nodule
parameters of future progression, apart from part-solid nature.
Conclusions This study confirms previously reported charac-
teristics of SSNs and associated factors in a European, routine
clinical population.
Key Points
• SSNs in women are significantly more often persistent com-
pared to men.
• SSN persistence is not associated with age or prior
malignancy.
•The majority of (persistent) SSNs are located in the upper
lung lobes.
• A part-solid nature is associated with future nodule growth.
• Progressive solitary SSNs are rare under the age of 50 years.
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Introduction
Subsolid pulmonary nodules (SSN) are a special subgroup of
lung nodules with specific characteristics distinct from solid
nodules, especially regarding growth rate and malignancy risk
[1–4]. SSNs are either transient or persistent, and represent
benign causes such as infection or focal fibrosis on the one
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hand, or (pre)malignant lesions lesions from the adenocarci-
nomatous spectrum on the other [5–7]. Regardless of the final
aetiology, every new and persistent SSN is an indication for
surveillance. Advances in CT technology and emerging data
on the meaning of this entity have increased awareness and
knowledge substantially in recent years [7]. Recently, guide-
lines are issued for SSN management [8, 9] based on the
currently available data. Briefly, this management mainly in-
volves imaging surveillance over several years, based on nod-
ule characteristics (i.e. pure ground-glass or part-solid nature)
and growth/transformation over time. If a malignancy is
suspected, additional examinations including biopsy, resec-
tion, and/or other therapy is recommended in a multidisciplin-
ary approach, based on the individual patient characteristics
and preferences [8, 9].
Although the available guidelines are meant to be applied
in clinical practice, most available data on SSNs originate
from lung cancer screening subjects, a different setting that
is likely not representative for daily clinical practice. The cur-
rently available non-screening data comes mainly from Asian
cohorts and from pathologically proven SSNs, which may
introduce a selection bias [10–15]. Also, most studies focus
on either pure or part-solid lesions and solely aim to identify
predictors for growth, malignancy, or invasiveness [12–14,
16, 17]. Although these studies elucidate important features
of SSNs, they do not provide a complete overview of the SSN
entity in routine clinical practice. It was our hypothesis that
clinically detected SSNs differed in their characteristics, be-
haviour, and/or patient characteristics from those detected in
the screening setting. Therefore, we aimed to provide data on
the generalizability of screening data by determining presence
and morphology of SSNs in a routine non-screening setting
and relate them to clinical and patient characteristics.
Methods
The local ethical institutional review board waived the need
for informed consent for this study, due to its retrospective
design.
Data collection
An automatic search was made for the description of a
subsolid nodule in all reports of chest CT examinations
obtained in adults in our academic hospital between June
2011 and November 2014. The dataset involved a routine
clinical patient population, in whom no selection was
made based on imaging indication, prior disease, or
outpatient/hospitalized status. All reports that contained
the terms Bground-glass^, Bsubsolid^, Bpart-solid^, or the
equivalent Dutch terms were selected. BNodule^ or
Blesion^ was not added in the search to avoid overly
narrowing the selection. One of the authors read all the
selected reports to determine whether the identified terms
where used to describe a nodular subsolid lesion (i.e. a
possible SSN). In case of doubt, the subject was included.
Subjects that originated from an ongoing lung cancer
screening trial were excluded, since these did not represent
routine clinical subjects. Basic clinical parameters such as
gender, age, and oncologic history were obtained from the
radiology information system.
Two observers (OMM and EThS; with >5 and >20 years of
experience in chest CT, respectively) in consensus scored all
included scans for the presence of a nodular subsolid lesion. In
case of discrepancy, the case was arbitrated by a third observer
(thoracic radiologist with >10 years of experience; PAJ). One
observer (OMM) then reviewed all available chest CT exam-
inations of the included cases to identify the first and last
available chest CT scan with thin-slice reconstructions on
which the SSN was visible. To determine longitudinal nodule
dimensions, these scans were subsequently processed by the
same observer using dedicated semi-automatic nodule soft-
ware (CIRRUS Lung, Diagnostic Image Analysis Group,
Nijmegen, The Netherlands, Fraunhofer MEVIS, Bremen,
Germany). The nodule segmentation technique has previously
been described in more detail, as was the interscan variation
using this software [18]. A subset of 10 subjects (i.e. 20 CT
scans) was analysed twice, to determine intraobserver
agreement.
During nodule segmentation, nodule location and mor-
phology (pure ground-glass or part-solid) were also anno-
tated. In case of multiple subsolid pulmonary nodules, the
largest or most dominant lesion was selected, where part-
solid lesions prevailed over pure ground-glass lesions.
Progression of the nodule was based on its volume increase
in the two CT scans, defined as an increase ≥28.6 % using
this specific software [18]. When a case showed equal or
decrease in total volume, but transition into a part-solid
lesion with growth of the solid component, it was also
classified as a progressive SSN. Growth rate of the nodules
was calculated as volume doubling time (VDT) using the
formula: VDT = ΔT * log2/log[V2/V1] with T in days and
V in cubic millimetres (mm3).
Scans were obtained on three MDCT scanners of the
same vendor (16-256 slice). According to protocol the
images were obtained at 100-120 kVp and 60-130 mAs,
depending on body weight. Thin-slice reconstructions
were made using a smooth reconstruction filter (C-filter,
Philips). Analyzed reconstructions had a slice thickness
of ≤1 mm. Because of differences in scan protocol re-
garding administration of intravenous contrast we were
unable to analyse longitudinal changes in nodule mass,
as the increased nodule density due to the enhancement
would largely influence the results when compared to
the same nodule in a non-enhanced CT.
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Data analysis
Continuous data is reported as median with interquartile range
(IQR), unless stated otherwise. Comparison of continuous da-
ta was performed with the Mann Whitney-U test, while pro-
portions were compared using the Chi-square test or Fisher
exact test, as appropriate. Intraobserver agreement was calcu-
lated using the intraclass correlation coefficient (ICC).
Logistic regression analysis was used to determine predictors
for future progression, using progression as outcome variable
and patient and lesion characteristics as potential predictors. A
p-value <0.05 was considered statistically significant.
Results
Data collection
In the 3-year period between June 2011 and November 2014 a
total of 16,890 chest CTs were obtained in 10,271 adults. In
2295 reports of 1683 unique patients at least one of the select-
ed search terms was identified. After case inclusion based on
report review, 189 remained. Visual scoring of these scans led
to exclusion of 56 cases, and there was discrepancy between
the two readers in 15. Refereeing by the third observer lead to
exclusion of 12 of the 15 discrepant cases, leaving a total of
121 subjects with an SSN (incidence = 1.2 %). Collecting
available imaging led to further exclusion of 23 cases, in
whom only a single chest CTwas obtained in the study period.
Of the remaining 98 cases, 83 proved persistent, while 15
disappeared on follow-up. Of the 83 persistent SSNs, four
subjects had only one CT scan of which the thin-slice data
was stored, impeding longitudinal volume quantification. In
5/79 of the semi-automatically processed persistent SSNs, it
proved technically impossible to reliably segment the SSN
due to a central localisation, scan quality, or breathing arte-
facts. Therefore, our final study population comprised 89 sub-
jects with 74 persistent and 15 transient SSNs. Figure 1 shows
the flow-chart of the inclusion process.
Subsolid pulmonary lesions
The total population that underwent chest CT in the study
period had a median age of 58 (45 – 68) years, range 18 to
99. The subpopulation with an SSN (N=121) was slightly
older (61.8 [52.4 – 69.6] years, p=0.01). There was no differ-
ence in gender distribution for those with and without an SSN
(M/F ratio 62/59 vs. 6035/4236; p=0.10). The excluded SSN
subjects (N=32) did not differ in age (p=0.49), but were more
often male (23/9 vs. 39/50, p<0.01) compared to the included
subjects. Table 1 summarizes the characteristics of the includ-
ed study subjects.
Transient versus persistent
Comparing the transient SSNs to the persistent nodules, there
was no significant difference in age (p = 0.22), location
(p=0.54), history of malignancy (p=0.14) or multiplicity
(p=0.37). However, women showed significantly more often
persistence of SSNs (47/50 vs. 27/39; p=0.002).
Persistent subsolid lesions
In the persistent SSN group, follow-up was available over a
median period of 19.6 (8.3 – 36.8) months. Initially, 52 were
pure ground-glass nodules (GGN), while 22 were part-solid
lesions. In total 35 SSNs were classified as progressive, either
due to increase in total lesion volume (N=28) or due to de-
velopment (N=3) or growth of the solid component (N=4).
The other 39/74 SSNs were classified as stable over a period
of 13.3 (6.0 – 27.8) months. See Fig. 2 for examples of dif-
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83 persistent 15 transient
74 with two or
more TS-CT
9 technically not suited
for segmentation
Fig. 1 Flow chart of study population selection SSN = subsolid
pulmonary nodule; FU = follow-up; TS-CT = thin-slice Computed
Tomography
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Semi-automated segmentation showed near perfect
intra-observer variability (ICC≥0.99). Maximum diameter
of the 74 nodules was at median 10.4 (7.8 – 14.3) mm,
while median volume was 588.7 (244.4 – 1529.9) mm3.
Part-solid lesions were significantly larger than pure GGN
(14.6 mm/1638.3 mm3 vs. 9.0 mm/382.9 mm3; p<0.001),
Table 1 Study population
characteristics Total (N = 89) Transient (N= 15) Persistent (N= 74)
Gender, N (%)
Male 39 (44) 12 (80) 27 (36)
Female 50 (46) 3 (20) 47 (64)
Age, years 61.6 [52.6–68.7] 56.6 [48.8–65.1] 62.0 [53.3–68.9]
Previous malignancy
Yes 45 (50) 5 (33) 40 (54)
No 44 (50) 10 (67) 34 (46)
Subtype
GGN 63 (71) 11 52 (70)
PS 26 (29) 4 22 (30)
Multiplicity
Solitary 60 (67) 12 (67) 48 (65)
Multiple 29 (33) 3 (33) 26 (35)
Location, N (%)
RUL 32 (36) 7 (47) 25 (34)
RML 4 (4) 2 (13) 2 (3)
RLL 11 (12) 1 (7) 10 (13)
LUL 33 (37) 3 (20) 30 (41)
LLL 9 (10) 2 (13) 7 (9)
Progressive, N (%) 35 N/A 35
Diameter, mm - - 10.4 [7.8–14.3]
Volume, mm3 - - 1530 [589–3220]
Fig. 2 Examples of a stable GGN (left), progressive GGN (middle), and
transformation of a GGN into a part-solid lesion over time (right). Panels
are axial, coronal, and sagittal projections for upper, middle, and lower
panels, respectively. (Left) Diameter/Volume 1 = 9.0 mm/382 mm3
Diameter/Volume 2 = 8.6 mm/338 mm3 Volume change (25.1 months)
= −12 % (Middle) Diameter/Volume 1 = 5.3 mm/79 mm3 Diameter/
Volume 2 = 11.1 mm/716 mm3 Volume change (36.8 months) = 803 %
(Right) Diameter/Volume 1 = 13.5 mm/1281 mm3 Diameter/Volume
2 = 16.4 mm/2287 mm3; Solid component: 6.2 mm/122 mm3 Volume
change (20.4 months) = 79 %
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and were more often progressive (15/22 vs. 20/52;
p=0.02).
Total volume change between the two CT scans was at
median +18 % (IQR -8 – +38; range -49 to +1244). The 35
progressive lesions showed a median VDT of 536 days (IQR
353 – 1301, range -784 to 5691) days. Two of the progressive
lesions showed a total volume decrease (VDT-784 and -660),
however, with a clear growth of the solid component.
Overall, persistent SSNs showed a clear preference for the
upper lobes (55/74, 74 %), and the SSNs that were not located
in the upper lobes were often found in the apical parts of the
lower lobes. SSN subtype and nodule progression did not
show an association with lobe distribution (p = 0.71 and
0.60, respectively). Figure 3 graphically shows nodule distri-
bution throughout the lungs.
No significant difference was found for the different age
groups, although the proportion of pure GGNs tends to de-
cline with higher age while part-solid lesions are more com-
monly present. Further, progressive lesions were mainly
found in the subjects aged 50 to 70 years (27/35, 77 %), while
these subjects comprised 65 % (49/74) of the total cohort.
Persistent SSNs are relatively rare under the age of 50 years
(10/89); however, they are present under the age of 35 years
(N=2). Out of the two progressive lesions that were found in
the <50 years old category, one was a 45-year-old man with
multiple progressive part-solid lesions representing neuroen-
docrine metastases. The other was a 33–year-old man with
metastasized non-seminoma who showed a nonspecific pure
GGN that showed limited volume increase (31 %) in
45 months of follow-up. Solitary part-solid lesions were not
found in the <50 years old subcategory. Figure 4 shows the
distribution of SSN subtypes over the different age categories.
Predictors of progression
Logistic regression analysis with nodule progression as out-
come variable and nodule characteristics (subtype, lesion vol-
ume, location, and multiplicity) as potential predictors,
showed that in our population only a part-solid nature was
associated with future progression (p=0.04). The other pa-
rameters did not reach significance.
Discussion
We present a descriptive paper on the subsolid pulmonary
nodule in a routine clinical setting obtained in a single aca-
demic institution. As most available data originates from lung
cancer screening or Asian study populations, we aimed to
evaluate whether the current knowledge on this relatively
new entity is generalizable to other practices. Clinical data
on SSN appearance and evolution over time may be of impor-
tance for an adapted and more personalized surveillance man-
agement in clinical subjects, where, for example, gender- or
age-defined subgroups can be identified that require different
follow-up intervals. In the current study we found that women
Fig. 3 Graph schematically
showing SSN distribution
throughout the lungs SSN =
Subsolid pulmonary nodule; RUL
= Right upper lobe; RML = Right
middle lobe; RLL = Right lower
lobe; LUL = Left upper lobe; LLL
= Left lower lobe; GGN =
Ground-glass nodule; PS = part-
solid nodule; PRGGN =
progressive ground-glass nodule;
PRPS = progressive part-solid
nodule
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more often show persistent lesions compared to men, and that
part-solid SSNs are larger and more often progressive com-
pared to pure GGNs. In our study a part-solid nature was the
single predictor of nodule growth over time.
Because of our retrospective study design and case selec-
tion based on the radiological reports, it is challenging to com-
ment on the true incidence of SSNs in clinical practice. In this
study we found an incidence of 1.2 % (121/10.271), which is
in line with available literature [9]. Nevertheless, highly vari-
able incidence – up to 38 % – is reported in the literature,
depending on the study population [7]. This high variability
also applies to the proportion of transient versus persistent
lesions [7]. Beyond study design and possible selection bias,
the inherent characteristics of a clinical population (e.g. im-
mune status) can influence the incidence and nodule type dis-
tribution of SSNs. This should always be kept in mind when
comparing study results.
Regarding persistence, we showed that a significantly
higher proportion of SSNs is persistent in women. This is in
line with Lee et al., who showed that male sex was associated
with the transient nature of part-solid SSNs in a screening
cohort [19]. They also found that younger age and multiplicity
were predictive for a transient nature; however, we found no
other differences in baseline characteristics between those
with a transient or persistent SSN. We believe this may well
be due to either our study population size and/or the fact that
we did include both types of SSNs.
The current guidelines of the Fleischner Society [8] and the
British Thoracic Society [9] treat men and women alike and
advise no lower age limit in their management recommenda-
tions –as is used in the management of solid pulmonary
nodules– because lung adenocarcinoma also occur in younger
non-smoking subjects. Comparing our findings to the current
knowledge, we also did not find a difference in gender distri-
bution among clinical subject with an SSN. Regarding age,
our study shows that persistent SSNs are relatively rare in
patients less than 50 years of age. When they do occur, we
found mostly non-progressive pure GGNs. However, our
study has limited follow-up and, therefore, some of these le-
sions potentially represent lesions of more importance in the
long run. Solitary lesions of short-term importance (i.e. single
progressive part-solid lesion, or transformation of a ground-
glass nodule into a part-solid lesion) were not present in our
cohort < 50 years. Progression was only seen in cases of
multiple lesions caused by metastases, in patients that are al-
ready under surveillance. In the middle aged patients (i.e. 50-
70 years of age), on the other hand, progressive lesions were
far more common; over half of the SSNs in this subgroup
showed progression during follow-up. Also, the GGN vs.
part-solid ratio tends to tip more to the latter with increasing
age. Taken together, these findings suggest that the worrisome
SSNs are mainly found in the aging lung and that age-
dependent surveillance intervals might well be appropriate.
However, our results are preliminary and future studies and
pooling of data could further elucidate this issue to determine
reliably surveillance subgroups. A strategy that potentially can
lower the number of CT scans and cumulative radiation expo-
sure in long-term follow-up, especially in younger subjects.
Another interesting finding was that nearly three quarters of
the SSNs were located in the right or left upper lobe. This
same pattern of lobar distribution for SSNs was present in
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Fig. 4 Graph showing the
distribution of SSN subtypes over
the different age categories. SSNs
tend to be mainly of pure ground-
glass morphology in the lower
age categories, with increasing
proportion of part-solid lesions in
the higher age groups. It is further
shown that the progressive lesions
(striped bars) are mainly found in
the middle (27 out of 35, 77 %)
and oldest age category (6 out 35,
17%), while they are scarce in the
youngest age group. SSN =
Subsolid pulmonary nodule;
GGN = Ground-glass nodule; PS
= Part-solid nodule
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explored. We now did not find an association between nodule
distribution and persistence, SSN subtype or progression.
Knowledge on upper lobe preference might support and focus
observers in SSN detection, but given the absence of clear
distribution patterns with regard to SSN morphology, it is
unlikely to be of major influence in adaptation of surveillance
management and is rightfully not part of the current
guidelines.
Nevertheless, the preference for the upper lobes might sug-
gest a relation with inhalation/smoking, as is described for
lung cancer, which is clearly most prevalent in the right upper
lobe [21]. Unfortunately, we cannot explain the upper lung
location preference with certainty and are unable to determine
a possible relationship with smoking as detailed smoking his-
tory is unknown in our clinical cohort. In general, limited data
are available on this issue [8, 9].
In the search for factors associated with future progression
of the nodule, we found only the part-solid nature of SSNs to
be associated. This is an already well known and extensively
reported parameter [11, 16, 20, 22] together with initial lesion
size [11, 12, 16, 20, 22, 23], which is fundamental for the
current management guidelines. We feel that the failure to
reproduce other previously reported predictors of progression
is likely due to our study population characteristics and rela-
tively small study size.
The strength of our study is that to our best knowledge we
are the first to present a descriptive study of SSN morphology
in a non-Asian and routine clinical population, not focused on
a specific SSN subtype and without selection on pathological
confirmation. Further, we have used semi-automated software
to determine which SSNs were progressive over time, instead
of using less reliable visual scores. Our study also has some
limitations. First, it is a retrospective, single-centre study, in
which we may have selected cases under possible reporting
bias. However, this is inherent to the current study design and
difficult to avoid when larger cohorts of SSNs are required.
Second, the study population is fairly small, which may either
reflect the low prevalence of these type of nodules or a
reporting bias. Nevertheless, we were able to include a suffi-
cient number of both GNN and part-solid SSNs with longitu-
dinal imaging data, not largely different from previous studies.
Third, given the retrospective analysis in a routine clinical
population we had no conclusive data on risk factors for lung
cancer such as family history or detailed smoking history.
Also, scan protocols regarding intravenous contrast adminis-
tration were not uniform, which impeded evaluation of lesion
mass. Additional to contrast injection, quantitative measure-
ments of subsolid nodules can be influenced by several other
factors including reconstruction protocol, dose, and tube volt-
age. Nevertheless, phantom experiments suggest that the in-
fluence is limited [24]. In our study we did not change tube
voltage. There are currently no data on the effect of contrast
injection for volume measurements of subsolid nodules, but
for solid nodules the volume difference is about 15 % [25].
Last, we do not have pathological confirmation of the pulmo-
nary nodules, which precludes conclusions on the prevalence
of (pre)malignancies in our subgroups. Nevertheless, we did
not introduce a selection bias by selecting only proven malig-
nancies and reflect daily practice in which unconfirmed le-
sions are encountered and surveyed.
In conclusion, our descriptive study provides complemen-
tary data on SSN morphology in a European, routine clinical
population. We confirm several previously reported character-
istics obtained in other study populations and provide addi-
tional data on subject age and lung distribution of SSNs.
Although our results are preliminary, these data might contrib-
ute to a more individualized approach of SSN management in
future routine clinical practice.
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